- Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basis
- Second quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%
- Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% – 7.7%, 6.2% – 7.2% and 3.5% – 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 – $8.30
WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025. The Company reported second quarter net sales of $2.077 billion, an increase of 7.0% over the prior year period, an increase of 5.4% on a constant currency1 basis and an increase of 2.8% on an organic constant currency basis. Net earnings for the second quarter were $152.8 million, or $411.2 million on an adjusted1 basis.
Diluted earnings per share were $0.77 for the second quarter, and adjusted1 diluted earnings per share were $2.07, an increase of 3.0%.
| _____________ |
| 1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release. |
“Our team delivered another solid quarter of growth, as our robust new product cycle drove significant acceleration in our U.S. Hips and Knees portfolios and continued strong growth in our global S.E.T. business,” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. “We are excited about the early customer enthusiasm and adoption for our broad new product portfolio, which we believe will continue to fuel our growth through 2025 and beyond. Customer-centric innovation like this is central to our long-term strategy, and the recent agreement to acquire Monogram Technologies not only marks a bold step forward in surgical robotics but also exemplifies our commitment to addressing the most meaningful challenges in healthcare.”
Recent Highlights
- Announced definitive agreement to acquire Monogram Technologies (NASDAQ: MGRM), an AI-driven robotics company, to expand Zimmer Biomet’s robotics suite with semi- and fully autonomous solutions, creating the broadest, most flexible suite of orthopedic robotics and navigation technologies to meet surgeons’ needs.
- Signed a strategic partnership with Getinge, a global medical technology company, where Zimmer Biomet will distribute Getinge’s Operating Room capital products to Ambulatory Surgery Center customers, creating a turnkey solution.
- Appointed Kevin Thornal as Group President, Global Businesses and the Americas.
- Launched “This, You Can Do,” a new direct-to-patient campaign and online resource to drive awareness of Zimmer Biomet’s Knee solutions in key U.S. markets.
- Named one of America’s Best Mid-Size Companies in 2025 by TIME; also certified as a Great Place to Work® in Colombia, India, Ireland, Poland, Puerto Rico, Saudi Arabia, Switzerland and the United States.
Geographic and Product Category Sales
The following sales tables provide results by geography and product category for the three and six-month periods ended June 30, 2025, as well as the percentage change compared to the applicable prior year period, on both a reported basis and a constant currency basis. Percentage change is also presented on an organic constant currency basis to exclude the impact on net sales from the April 2025 acquisition of Paragon 28.
